Division of Hematology

With an established reputation for advancing research in several areas critical to caring for children with benign hematologic disorders, the Division of Hematology at Children’s Hospital of Philadelphia continues to fortify and expand its groundbreaking program. Investigators in the Division leverage a vast amount of expertise and innovation to propel their current research themes that center on novel therapeutics for a variety of disorders, in collaboration with several divisions at CHOP and the University of Pennsylvania, to improve care for patients.

In particular, research in the Division focuses on novel therapeutics for hemophilias and hemoglobinopathies. Gene therapy for hemophilias has led to a successful commercial enterprise, and the current and future research efforts stemming from this enterprise include novel genetic therapeutic interventions, drug development, and clinical trials. With thriving and interconnected research in hemostasis and thrombosis, the coordinated program between CHOP and Penn represents the largest center in the field.

Additional key research areas in the Division include investigations into novel therapeutic interventions for other blood diseases, including bone marrow failure and inherited platelet disorders; the blood products for induced pluripotent stem cells; improved care for patients with sickle cell disease and for those patients in intensive care with hemostatic/thrombotic challenges.